Acute Hypercalcaemia Protocol Hydrate · Block · Eliminate · v1.0
Workflow: Enter the patient's calcium, albumin, renal function, ECG findings, symptoms, and suspected aetiology to generate a stepwise emergency protocol covering aggressive hydration, anti-resorptive therapy, and dialysis indications.
1. Calcium & Albumin
2. Clinical Status
3. Suspected Aetiology
The Two Causes That Cover 90%

Primary hyperparathyroidism and malignancy account for approximately 90% of all hypercalcaemia. The clinical distinction is critical because management differs fundamentally. PTH level is the key discriminator: PTH elevated or inappropriately normal = primary hyperparathyroidism; PTH suppressed (low) = malignancy or other non-PTH cause. Always send PTH, PTHrP, 25-OH vitamin D, and 1,25-dihydroxyvitamin D together.

FeaturePrimary HyperparathyroidismMalignancy-Associated
OnsetChronic, indolentAcute, rapid rise
Calcium levelUsually mild (10.5-12 mg/dL)Often severe (> 14 mg/dL)
PTHElevated or inappropriately normalSuppressed (low)
PTHrPNormalElevated (humoral hypercalcaemia of malignancy)
ChlorideElevated (> 103) due to bicarbonaturiaNormal
Definitive treatmentParathyroidectomyTreat underlying malignancy
The Physiology of Dehydration in Hypercalcaemia

Hypercalcaemia causes a vicious cycle of dehydration: (1) Calcium impairs renal concentrating ability (nephrogenic diabetes insipidus), causing polyuria. (2) Hypercalcaemia causes nausea and vomiting, reducing fluid intake. (3) Dehydration reduces GFR, decreasing renal calcium excretion. (4) Higher serum calcium worsens symptoms further. Aggressive IV saline hydration breaks this cycle by restoring GFR and promoting calciuresis. This is always Step 1, regardless of severity.

Bisphosphonate Therapy: The Definitive Agent

Zoledronic acid (Zometa) 4 mg IV over 15 minutes is the most potent bisphosphonate available. It inhibits osteoclast-mediated bone resorption. However, its onset is 2 to 4 days (peak effect at 4 to 7 days). This is why calcitonin is used as a bridge (onset 4 to 6 hours) while waiting for bisphosphonate effect. Duration: 2 to 4 weeks per dose.

Alternative: Pamidronate 60 to 90 mg IV over 2 to 4 hours. Slightly less potent but available at lower cost in Indian hospitals.

⚠ Bisphosphonate Contraindication: In severe renal impairment (eGFR < 30 or Cr > 4.5 mg/dL), zoledronic acid carries significant nephrotoxicity risk. Use Denosumab 120 mg SC instead (RANKL inhibitor, not renally cleared). Onset: 2 to 4 days.
"Stones, Bones, Groans, and Psychiatric Overtones"

The classic mnemonic for hypercalcaemia symptoms: Stones (nephrolithiasis, nephrocalcinosis) · Bones (bone pain, osteitis fibrosa cystica, pathological fractures) · Groans (abdominal pain, constipation, nausea, pancreatitis, peptic ulcer disease) · Psychiatric overtones (anxiety, depression, confusion, psychosis, coma). Also: polyuria, polydipsia, shortened QT, band keratopathy.

Hypercalcaemia in TB and Granulomatous Disease

In Indian hospitals, tuberculosis is an important and often overlooked cause of hypercalcaemia. Activated macrophages in granulomata express 1-alpha hydroxylase, converting 25-OH vitamin D to active 1,25-dihydroxyvitamin D independently of PTH regulation. The result: unregulated calcium absorption. Check 1,25-dihydroxyvitamin D (will be high) and PTH (will be suppressed). Treatment: corticosteroids (Prednisolone 20 to 40 mg/day) rapidly reduce 1,25-D production and lower calcium. Also seen in sarcoidosis, Wegener granulomatosis, and fungal infections.

Abbreviations: Ca (Calcium) · PTH (Parathyroid Hormone) · PTHrP (Parathyroid Hormone-related Peptide) · GFR (Glomerular Filtration Rate) · RANKL (Receptor Activator of NF-kB Ligand) · TdP (Torsades de Pointes)
Algorithm References & Evidence Base
  1. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723.
  2. Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7(10):1722-1729.
  3. Maier JD, Levine SN. Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy. J Intensive Care Med. 2015;30(5):235-252.
  4. Walker MD, Shane E. Hypercalcemia: A Review. JAMA. 2022;328(16):1624-1636.
  5. Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med. 2000;6(5):442-447.
How to Cite This Tool

AMA Style:
Umakanth S. Acute Hypercalcaemia Protocol. MEDiscuss. Published 2026. Accessed .

Vancouver Style:
Umakanth S. Acute Hypercalcaemia Protocol [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

Category Therapeutic Pathways & Algorithms
Specialties Internal Medicine, Oncology, Nephrology, Critical Care
Status New Pathway